Posted On: 10/04/2014 8:33:23 AM
Post# of 30066
Lympro CLIA package, 2 Orphan Drug Applications for MANF, additional MANF data, IND for Eltoprazine. If that all happens, it will be a very solid quarter.
Lots in between the lines that could come to fruition as well. Build out of ICON relationship for Lympro (Ex-US deal?). Interest from BP regarding Eltoprazine. This may not happen until 2015, but with their work on ADHD after submission for LID, Eltoprazine becomes extremely attractive. MANF biz dev activities have been mentioned, and with 2 potential orphan indications, interest will be accelerated with BP. Other orphan ocular indications will certainly garner the attention of BP players in that market. Expecting to hear something about at least one grant soon. They have been hard at work on that for some time now.
Lots in between the lines that could come to fruition as well. Build out of ICON relationship for Lympro (Ex-US deal?). Interest from BP regarding Eltoprazine. This may not happen until 2015, but with their work on ADHD after submission for LID, Eltoprazine becomes extremely attractive. MANF biz dev activities have been mentioned, and with 2 potential orphan indications, interest will be accelerated with BP. Other orphan ocular indications will certainly garner the attention of BP players in that market. Expecting to hear something about at least one grant soon. They have been hard at work on that for some time now.
(0)
(0)
